| Name | Title | Contact Details |
|---|
M Jacobson Usa is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At CareFusion, we are united in our vision to improve the safety and lower the cost of healthcare for generations to come. Our 16,650 worldwide employees are passionate about healthcare and helping those that deliver it - from the hospital pharmacy to the intensive care unit, the operating theatre to the patient bedside and beyond. Our proven product families include Intermed, AVEA, VELA, SensorMedics, AirLife and respiratory products, Pyxis automated dispensing and patient identification systems, V. Mueller and Snowden-Pencer surgical instruments, Achieve Temno and Jamshidi, and the PleurX drainage system and the Alaris IV pumps (not sold in Brazil). To make global healthcare better, we partner with our customers to provide clinically differentiated respiratory solutions to help optimize patient care, improve medication management and lower the cost in procedural areas.
Regenesis Biomedical Inc is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.